Literature DB >> 24456122

Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.

Upendra Srinivas1, Adarsh Barwad, Sushma Venkata Pubbaraju.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24456122     DOI： 10.1111/bjh.12742

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  Paratrabecular myelofibrosis and occult mastocytosis are strong morphological clues to suspect FIP1L1-PDGFRA translocation in hypereosinophilia.

Authors:  Sreejesh Sreedharanunni; Man Updesh Singh Sachdeva; Saniya Sharma; Sonia Rana; Rajeev Sandal; Narender Kumar; Prashant Sharma; Shano Naseem; Jasmina Ahluwalia; Reena Das; Pankaj Malhotra; Neelam Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2019-12-04       Impact factor: 0.900

2.  Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.

Authors:  David E Gerber; Paul Swanson; Ariel Lopez-Chavez; Lucas Wong; Afshin Dowlati; Nathan A Pennell; Damien M Cronier; Amy Qin; Robert Ilaria; Jan Cosaert; Ashwin Shahir; Maria Q Baggstrom
Journal:  Lung Cancer       Date:  2017-07-18       Impact factor: 5.705

3.  Complete response of myeloid/lymphoid neoplasms with PDGFRA rearrangement presenting as leukemia/myeloid sarcoma to imatinib monotherapy.

Authors:  Rui Ma; Xiao-Jun Huang; Jin-Song Jia; Jun Kong; Ya-Zhen Qin; Hao Jiang
Journal:  Chin Med J (Engl)       Date:  2019-10-20       Impact factor: 2.628
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.